The Btk inhibitor 1 R enantiomer hydrochloride is primarily utilized in the field of oncology and immunology for its targeted therapeutic effects. It is specifically designed to inhibit Bruton's tyrosine kinase (Btk), an enzyme crucial for the survival and proliferation of certain cancer cells, particularly in B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By blocking Btk, this compound disrupts signaling pathways that promote tumor growth and survival, making it a valuable tool in cancer treatment. Additionally, it shows promise in managing autoimmune diseases by modulating B-cell activity, which plays a key role in immune system dysregulation. Its R enantiomer form ensures enhanced potency and selectivity, improving its efficacy and reducing off-target effects in clinical applications.